Listed by the USPTO as NOAKES, SUZANNE MARIE
Tech Center 1700 • Art Units: 1652 1653 1656 1683 1759 1799
This examiner grants 73% of resolved cases
NOAKES, SUZANNE MARIE is assigned to tech center 1700 and art unit 1652. The record covers 1082 resolved cases and shows an allowance rate of 73.4%. The median time to allowance is 946 days. Interview lift is 18.3%, indicating that interviews have been associated with improved allowance outcomes in this substantial record.
The leading companies are Novozymes A/S, Beam Therapeutics Inc., and University of Massachusetts. The principal firms are WENDEROTH, LIND & PONACK L.L.P., Berg Hill Greenleaf & Ruscitti LLP, and CHALKER FLORES, LLP. Practitioners can use these recurring applicants and counsel as a guide to relevant prosecution experience. The timing and allowance measures support portfolio forecasting, while the interview figure supports purposeful examiner engagement.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18743008 | ACTIVATABLE NANOREPORTERS FOR REAL-TIME TRACKING OF MACROPHAGE PHENOTYPIC STATES ASSOCIATED WITH DISEASE PROGRESSION | Non-Final OA | University of Massachusetts |
| 19071092 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | Non-Final OA | Halozyme, Inc. |
| 18848533 | NEW GLUTAMINE SYNTHETASE VARIANTS AS SELECTION MARKER | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18458443 | PLANT GROWTH PROMOTER PRODUCTION METHOD, PLANT GROWTH PROMOTER, AND PLANT GROWTH PROMOTING METHOD | Non-Final OA | Panasonic Intellectual Property Management Co., Ltd. |
| 18309003 | RECOMBINANT PROTEINS FOR QUANTIFICATION OF PROTEIN LEVELS | Non-Final OA | Genentech, Inc. |
| 17822992 | Methods For The Identification Of UBQLN2-Mediated Amyotrophic Lateral Sclerosis (ALS) | Final Rejection | The Regents of the University of Colorado, a body corporate |
| 18261264 | SUPRAMOLECULAR ASSEMBLIES, COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 18838044 | PROCESS FOR WHOLE-CELL BIOSYNTHESIS OF STYRENE | Non-Final OA | SHELL USA, INC. |
| 19064858 | GTP CYCLOHYDROLASE-CLEAVING PROTEASES | Non-Final OA | Children's Medical Center Corporation |
| 19103587 | EXPRESSION SYSTEMS FOR PHOSPHATASES | Non-Final OA | INTERNATIONAL N&H DENMARK APS |
| 18249988 | CARRIER PEPTIDE FRAGMENT AND USE THEREOF | Non-Final OA | TOAGOSEI CO., LTD. |
| 18262051 | LIPASE WITH LOW MALODOR GENERATION | Non-Final OA | Novozymes A/S |
| 17923489 | MEDICAL CLEANING COMPOSITION, USE AND METHOD OF CLEANING | Non-Final OA | Novozymes A/S |
| 18993653 | BIOSENSOR COMPRISING A MODIFIED BETA-LACTAMASE AND USES THEREOF | Non-Final OA | THE HONG KONG POLYTECHNIC UNIVERSITY |
| 17786997 | A RECOMBINANT FILAMENTOUS FUNGUS FOR PRODUCING ETHANOL AND ITS CONSTRUCTION AND APPLICATION | Final Rejection | TIANJIN INSTITUTE OF INDUSTRIAL BIOTECHNOLOGY, CHINESE ACADEMY OF SCIENCES |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy73.4% of resolved applications examined by Suzanne Marie Noakes were allowed (1,082 resolved cases), compared with 53.5% across Art Unit 1652 over the last five years.
This examiner's interview lift is +18.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Suzanne Marie Noakes took 946 days on average from filing to allowance.
Suzanne Marie Noakes examines applications in Art Unit 1652 in Tech Center 1700 (Chemistry & Materials).
